drugset / Trial / NCT00290043

Glulisine Pre- and Postmeal

NCT00290043

Phase 1 Completed 20 enrolled Sanofi
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate in type 1 diabetic patients the glucodynamic response to HMR1964 insulin and RHI (HOE31HPR100) injected subcutaneously before and after a standard meal

Timeline

Start
2001-12
Primary completion
Completion
2002-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin glulisine Protein / enzyme biologic 0.15 iu/kg Subcutaneous